Menu Search
Equities

Essex Bio-Technology Ltd

1061:HKG.HZ

Essex Bio-Technology Ltd

Actions
  • Price (HKD)2.55
  • Today's Change-0.05 / -1.92%
  • Shares traded322.00k
  • 1 Year change-29.17%
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Essex Bio-Technology Ltd is an investment holding company principally engaged in the manufacture and sales of biopharmaceutical products for the treatment and healing of surface wounds and eye wounds. The Company develops biopharmaceutical drugs based on recombinant deoxyribonucleic acid (DNA) technology. The main brands of the Company's products are Beifuji, Beifushu and Beifuxin. The Company operates through two segments. The Surgical segment is engaged in the manufacture and sale of Beifuji spray, Beifuji lyophilised powder and Beifuxin gel. The Ophthalmology segment is engaged in the manufacture and sale of Beifushu eye drops, Beifushu eye gel and Beifushu unit-dose eye drops.

  • Revenue in HKD (TTM)1.71bn
  • Net income in HKD275.26m
  • Incorporated2000
  • Employees1.48k
  • Location
    Essex Bio-Technology LtdRoom 2818,Chn Mrchnts Twr,Shn Tk Ctr168-200 Connaught Road CentralCentral Hong KongHKG
  • Phone+852 25877838
  • Fax+852 25877363
  • Websitehttp://www.essexbio.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.